• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by FutureTech II Acquisition Corp. (Amendment)

    3/6/24 10:17:28 AM ET
    $FTII
    Blank Checks
    Finance
    Get the next $FTII alert in real time by email
    SC 13G/A 1 tm248069d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G 

    (Amendment No. 1 )*

     

    Under the Securities Exchange Act of 1934

     

     

    FutureTech II Acquisition Corp.

     
      (Name of Issuer)  
         
     

    Class A 

     
      (Title of Class of Securities)  
         
     

    36119D103

     
      (CUSIP Number)  
         
      3/6/2024  
      (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 36119D103    

     

    1

    NAME OF REPORTING PERSONS.
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

    Calamos Market Neutral Income Fund, a series of Calamos Investment Trust

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨ 

    (b) ¨ 

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Massachusetts, U.S.A.

    NUMBER OF SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    500,000

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    500,000

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    21.6%

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)                            ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    21.6%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IV

           

    Page 2 of 6

     

     

    CUSIP No. 36119D103    

     

    Item 1. (a) Name of Issuer
         
        FutureTech II Acquisition Corp.
         
      (b) Address of Issuer’s Principal Executive Offices
         
        128 Gail Drive
        New Rochelle, NY, 10805
         
    Item 2. (a) Name of Person Filing
         
        Calamos Market Neutral Income Fund, a series of Calamos Investment Trust
         
        This statement is being filed pursuant to a Joint Filing Agreement (attached as Exhibit 1 and incorporated herein by reference) between (i), (ii), and (iii), (sometimes collectively referred to as the “Reporting Persons”).
         
      (b) Address of Principal Business Office or, if none, Residence
         
        2020 Calamos Court
        Naperville, IL 60563
         
      (c) Citizenship
         
        See Item 2(a) above. Massachusetts, U.S.A.
         
      (d) Title of Class of Securities
         
        Class A
         
      (e) CUSIP Number
         
        36119D103

     

    Item 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Exchange Act.
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.
         
    (d) x Investment company registered under section 8 of the Investment Company Act.
         
    (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
         
    (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act.
         
    (j) ¨ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
         
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     
    Not applicable.

     

    Page 3 of 6

     

     

    CUSIP No. 36119D103    

     

    Item 4. Ownership.  
           
    The following information is provided as of February 29, 2024:
           
    The following sets forth the share ownership as to each of the Reporting Persons:
           
      (a) Amount beneficially owned: 21.6%
           
      (b) Percent of class: 21.6%
           
      (c) Number of shares as to which the person has:
           
        (i) sole power to vote or to direct the vote of:
           
          500,000 ordinary shares
           
        (ii) shared power to vote or to direct the vote of:
           
          0 ordinary shares
           
        (iii) sole power to dispose or to direct the disposition of:
           
          500,000 ordinary shares
           
        (iv) shared power to dispose or to direct the disposition of:
           
          0 ordinary shares
           
    Item 5. Ownership of Five Percent or Less of a Class.
           
      Not applicable.
           
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
           
      Not applicable.
           
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
           
      Not applicable.

     

    Page 4 of 6

     

     

    CUSIP No. 36119D103    

     

    Item 8. Identification and Classification of Members of the Group.
           
      Not applicable.
           
    Item 9. Notice of Dissolution of Group.
           
      Not applicable.
           
    Item 10. Certification.
           
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 5 of 6

     

     

    CUSIP No. 36119D103    

     

    SIGNATURE

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: March 6, 2024

     

      Calamos Market Neutral Income Fund, a series of Calamos Investment Trust
         
      By: /s/ Susan Schoenberger
      Name: Susan Schoenberger
      Title: Assistant Secretary

     

    Page 6 of 6

     

    Get the next $FTII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTII

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FTII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & CFO Chen Ray Lei converted options into 380,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 8:42:18 PM ET
    $FTII
    Blank Checks
    Finance

    Large owner Radu Zachary C. converted options into 2,445,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 6:30:25 PM ET
    $FTII
    Blank Checks
    Finance

    Director Bush Neil converted options into 10,000 shares (SEC Form 4)

    4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)

    2/6/25 4:48:44 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    SEC Filings

    View All

    SEC Form 10-Q filed by FutureTech II Acquisition Corp.

    10-Q - FutureTech II Acquisition Corp. (0001889450) (Filer)

    8/22/25 5:10:57 PM ET
    $FTII
    Blank Checks
    Finance

    FutureTech II Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - FutureTech II Acquisition Corp. (0001889450) (Filer)

    8/18/25 5:26:57 PM ET
    $FTII
    Blank Checks
    Finance

    FutureTech II Acquisition Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - FutureTech II Acquisition Corp. (0001889450) (Filer)

    8/15/25 6:41:34 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance

    New York, New York, Dec. 04, 2024 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (the "Company") (NASDAQ:FTII), today announced that it received an expected deficiency notification letter from the staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on November 27, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the "SEC") on November 15, 2024. Th

    12/4/24 1:35:00 PM ET
    $FTII
    Blank Checks
    Finance

    Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity

     -Longevity Biomedical, Inc. is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase the health span for the rapidly growing global aging population.    -Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.    -Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, and Phase 2 start for LBI-001 in retinal vein occlusion.    -Seasoned management team of m

    9/20/24 2:55:00 PM ET
    $FTII
    Blank Checks
    Finance

    FutureTech II Acquisition Corp. Confirms Funding and Extension of Period to Complete Initial Business Combination

    New Rochelle, NY, May 17, 2023 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (NASDAQ:FTIIU) (the "Company"), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, announced today that it caused to be deposited $1,150,000 into the Company's trust account for its public stockholders, representing $0.10 per public share, allowing the Company to extend by three months (from May 18, 2023 to August 18, 2023) the period of time the Company has to consummate its initial business combination (the "Extension"). The Extension is the second of two

    5/17/23 4:05:00 PM ET
    $FTII
    Blank Checks
    Finance

    $FTII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FutureTech II Acquisition Corp.

    SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/14/24 1:07:48 PM ET
    $FTII
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by FutureTech II Acquisition Corp.

    SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/13/24 4:51:36 PM ET
    $FTII
    Blank Checks
    Finance

    SEC Form SC 13G filed by FutureTech II Acquisition Corp.

    SC 13G - FutureTech II Acquisition Corp. (0001889450) (Subject)

    11/13/24 4:41:47 PM ET
    $FTII
    Blank Checks
    Finance